57231-31-9 Usage
Description
(S)-1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methylisoquinoline-6,7-diol is a complex organic compound characterized by a tetrahydroisoquinoline core and hydroxyl groups attached to the benzene ring. It is a derivative of isoquinoline and contains a methyl group. The presence of hydroxyl groups suggests that it may exhibit antioxidant properties, while its structural resemblance to neurotransmitters and other biologically active compounds indicates potential pharmacological or neurochemical effects. Overall, this chemical is a potentially bioactive compound with a complex structure and therapeutic application prospects.
Uses
Used in Pharmaceutical Industry:
(S)-1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methylisoquinoline-6,7-diol is used as a potential therapeutic agent for various conditions due to its antioxidant properties and structural similarity to neurotransmitters and other biologically active compounds. Its potential pharmacological or neurochemical effects make it a candidate for further research and development in the pharmaceutical industry.
Used in Chemical Research:
In the field of chemical research, (S)-1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methylisoquinoline-6,7-diol serves as a valuable compound for studying its antioxidant properties and exploring its potential interactions with biopolymers and macromolecules. This research could lead to a better understanding of its mechanisms of action and pave the way for novel applications in various industries.
Used in Drug Delivery Systems:
(S)-1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methylisoquinoline-6,7-diol can be utilized in the development of novel drug delivery systems to enhance its bioavailability and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, the compound's delivery, efficacy, and overall performance against specific conditions can be improved, making it a promising candidate for advanced drug delivery applications.
Check Digit Verification of cas no
The CAS Registry Mumber 57231-31-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,2,3 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 57231-31:
(7*5)+(6*7)+(5*2)+(4*3)+(3*1)+(2*3)+(1*1)=109
109 % 10 = 9
So 57231-31-9 is a valid CAS Registry Number.
InChI:InChI=1/C17H19NO4/c1-18-5-4-11-8-16(21)17(22)9-12(11)13(18)6-10-2-3-14(19)15(20)7-10/h2-3,7-9,13,19-22H,4-6H2,1H3/t13-/m0/s1
57231-31-9Relevant articles and documents
Compositions and methods for producing benzylisoquinoline alkaloids
-
Page/Page column 4, (2016/05/19)
The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.
Biosynthesis. Part 24. Speculative Incorporation Experiments with 1-Benzylisoquinolines and a Logical Approach via C6-C2 and C6-C3 Precursors to the Biosynthesis of Hasubanonine and Protostephanine
Battersby, Alan R.,Jones, Raymond C. F.,Kazlauskas, Rymantas,Thornber, Craig W.,Ruchirawat, Somsak,Staunton, James
, p. 2016 - 2029 (2007/10/02)
Many possible 1-benzyltetrahydroisoquinolines have been examined as possible advanced precursors of the alkaloids hasubanonine (1) and protostephanine (2) in Stephania japonica plants, but none was incorporated significantly.Administration of various precursor molecules having only one aromatic ring, such as tyrosine, has demonstrated that both alkaloids are derived from two different C6-C2 biogenetic units.The subsequent failure of further 1-benzyltetrahydroisoquinolines and bisphenethylamines to be incorporated suggested the intermediacy of either (a) modified 1-benzylisoquinolines or (b) trioxygenated C6-C2 building blocks.Precursors designed to examine the first possibility, such as 1-benzyl-3,4-dihydroisoquinolines or 1-benzyl-1-carboxytetrahydroisoquinolines, were not incorporated into (1) and (2) whereas two 3',4',5'-trioxygenated 2-phenylethylamines were incorporated.These findings allow further delineation of the requirements for later precursors of the alkaloids (1) and (2).
